Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adults
NCT02436928Phase 2Completed
- Sponsor
- Medigen Biotechnology
- Start
- Apr 2015
- Primary completion
- Feb 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AT-501 in avian influenza A H7N9 virus infection (H7N9), sponsored by Medigen Biotechnology. Started Apr 2015; status: completed.
02
Drugs
AT-501
03
Conditions
avian influenza A H7N9 virus infection (H7N9)
Beyond the preview
Go deeper on NCT02436928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02436928.